Judd Dayton Acquires 18,097 Shares of Lifevantage (NASDAQ:LFVN) Stock

Lifevantage Corporation (NASDAQ:LFVN) Director Judd Dayton bought 18,097 shares of the business’s stock in a transaction on Friday, February 27th. The stock was bought at an average price of $4.63 per share, for a total transaction of $83,789.11. Following the purchase, the director directly owned 69,859 shares of the company’s stock, valued at $323,447.17. The trade was a 34.96% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Judd Dayton also recently made the following trade(s):

• On Monday, March 2nd, Judd Dayton purchased 10,500 shares of Lifevantage stock. The shares were purchased at an average cost of $4.53 per share, with a total value of $47,565.00.
• On Thursday, February 26th, Judd Dayton purchased 4,600 shares of Lifevantage stock. The stock was purchased at an average price of $4.58 per share, for a total transaction of $21,068.00.

Lifevantage Stock Up 6.2%

Shares of Lifevantage stock opened at $4.80 on Wednesday. The company has a market cap of $61.39 million, a P/E ratio of 8.00 and a beta of 0.35. The firm’s 50 day moving average price is $5.59 and its 200-day moving average price is $7.80. Lifevantage Corporation has a 52-week low of $3.90 and a 52-week high of $17.64.

Lifevantage (NASDAQ:LFVN) last announced its earnings results on Wednesday, February 4th. The company reported $0.15 earnings per share for the quarter, missing the consensus estimate of $0.22 by ($0.07). The firm had revenue of $48.93 million during the quarter, compared to analyst estimates of $54.40 million. Lifevantage had a net margin of 3.74% and a return on equity of 29.59%. Lifevantage has set its FY 2026 guidance at 0.600-0.800 EPS.

Lifevantage Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 16th. Investors of record on Monday, March 2nd will be given a dividend of $0.045 per share. This represents a $0.18 annualized dividend and a yield of 3.8%. The ex-dividend date of this dividend is Monday, March 2nd. Lifevantage’s dividend payout ratio is currently 30.00%.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on LFVN. Weiss Ratings restated a “hold (c)” rating on shares of Lifevantage in a research note on Monday, December 29th. Wall Street Zen downgraded shares of Lifevantage from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Loop Capital set a $5.00 price target on shares of Lifevantage in a report on Thursday, February 5th. Finally, Lake Street Capital reiterated a “buy” rating on shares of Lifevantage in a research note on Thursday, February 5th. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $5.00.

Institutional Trading of Lifevantage

Hedge funds and other institutional investors have recently made changes to their positions in the business. Police & Firemen s Retirement System of New Jersey acquired a new position in Lifevantage during the second quarter valued at $31,000. JPMorgan Chase & Co. raised its stake in shares of Lifevantage by 870.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 5,016 shares of the company’s stock valued at $66,000 after buying an additional 4,499 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Lifevantage in the 2nd quarter valued at about $76,000. BNP Paribas Financial Markets boosted its stake in shares of Lifevantage by 2,555.8% in the second quarter. BNP Paribas Financial Markets now owns 6,135 shares of the company’s stock worth $80,000 after buying an additional 5,904 shares during the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in Lifevantage during the first quarter worth about $97,000. Institutional investors and hedge funds own 35.32% of the company’s stock.

About Lifevantage

LifeVantage Corporation is a publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model. The company’s flagship offering, Protandim®, is formulated to activate the Nrf2 pathway, which is associated with cellular defense processes. LifeVantage also markets the PhysIQ® line for metabolism and body composition support and the TrueScience® skincare regimen, targeting a range of health and wellness needs.

Founded in 1999 and headquartered in Sandy, Utah, LifeVantage combines research in nutrigenomics with a network of independent distributors to bring its products to market.